Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

Cardiovasc Diabetol. 2022 Apr 8;21(1):50. doi: 10.1186/s12933-022-01481-0.


The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18-19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year's focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1-5, and STEP 1-5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed.Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10-11, 2022 ( ).

Keywords: Cardiovascular disease; Chronic kidney disease; Diabetes; GLP-1 receptor agonist; Heart failure; Living guidelines; Mineralocorticoid receptor antagonist; Obesity; SGLT2 inhibitor; Tirzepatide.

Publication types

  • Congress
  • Letter

MeSH terms

  • Blood Glucose
  • COVID-19
  • Cardiovascular Diseases* / drug therapy
  • Clinical Trials as Topic
  • Diabetes Mellitus* / drug therapy
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
  • Treatment Outcome


  • Blood Glucose
  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors